

Q-101 B2

10

Sub. D1

15

20

25

2. Recombinant live vaccine according to Claim 1, wherein the nucleotide sequence or sequences is/are inserted into at least one site selected from the group consisting of ORF3, ORF5, thymidine kinase gene and sequence situated between the CHV ORF19 and the CHV ORF22, by simple insertion or after total or partial deletion.

15 3. Recombinant live vaccine according to Claim 1
wherein, to express the inserted sequence, the
vector comprises a strong eukaryotic promoter.

4. Recombinant live vaccine according to claim 3, wherein the strong promoter is a CMV immediate-early promoter, preferably the murine or human CMV immediate-early promoter.

5. Recombinant live vaccine according to
claim 1, which comprises at least two
nucleotide sequences inserted into at least one site
under the control of different eukaryotic promoters.

6. Recombinant live vaccine according to Claim 5, wherein the eukaryotic promoters are CMV immediate-early promoters of different animal origins.

7. Recombinant live vaccine according to Claim 5
which comprises a first nucleotide sequence
associated with a CMV immediate-early promoter and
another nucleotide sequence associated with another
promoter, the two promoters in this case having their
5' ends adjacent.

35 8. Recombinant live vaccine according to claim
1, which comprises a nucleotide sequence
coding for an antigenic polypeptide of a canine
pathogenic agent, this sequence being inserted into one
of the sites.

10

15

16. DNA fragment consisting of all or part of the sequence defined by positions 583 to 4173 on the sequence SEQ ID No. 1.